RU2017112748A - Композиции онапристона пролонгированного действия и способы - Google Patents

Композиции онапристона пролонгированного действия и способы Download PDF

Info

Publication number
RU2017112748A
RU2017112748A RU2017112748A RU2017112748A RU2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A RU 2017112748 A RU2017112748 A RU 2017112748A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
onapristone
sustained
release pharmaceutical
day
Prior art date
Application number
RU2017112748A
Other languages
English (en)
Russian (ru)
Other versions
RU2017112748A3 (OSRAM
Inventor
Александер ЖУКИВСКИ
Стефан ПРОНЮК
Original Assignee
Арно Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арно Терапьютикс, Инк. filed Critical Арно Терапьютикс, Инк.
Publication of RU2017112748A publication Critical patent/RU2017112748A/ru
Publication of RU2017112748A3 publication Critical patent/RU2017112748A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017112748A 2014-11-17 2015-11-16 Композиции онапристона пролонгированного действия и способы RU2017112748A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080868P 2014-11-17 2014-11-17
US62/080,868 2014-11-17
PCT/US2015/060940 WO2016081383A1 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods

Publications (2)

Publication Number Publication Date
RU2017112748A true RU2017112748A (ru) 2018-12-19
RU2017112748A3 RU2017112748A3 (OSRAM) 2019-06-26

Family

ID=56014429

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112748A RU2017112748A (ru) 2014-11-17 2015-11-16 Композиции онапристона пролонгированного действия и способы

Country Status (11)

Country Link
US (3) US10786461B2 (OSRAM)
EP (1) EP3247362A4 (OSRAM)
JP (1) JP6655075B2 (OSRAM)
KR (1) KR20170084086A (OSRAM)
CN (2) CN106999501B (OSRAM)
AU (2) AU2015350241B2 (OSRAM)
CA (1) CA2966753A1 (OSRAM)
HK (1) HK1246653A1 (OSRAM)
MX (1) MX391191B (OSRAM)
RU (1) RU2017112748A (OSRAM)
WO (1) WO2016081383A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
ES8502612A1 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
US4742000A (en) 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
DE3630030A1 (de) 1986-09-01 1988-03-03 Schering Ag 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
DE4008584A1 (de) 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1053450C (zh) 1992-11-19 2000-06-14 北京第三制药厂 17位取代11β-取代芳香基-4,9-雌甾二烯类化合物的全合成法
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
PT787002E (pt) * 1994-10-24 2007-03-30 Schering Ag Antagonistas de progesterona competitivos para controlo de fertilidade feminina orientado pela necessidade
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
UY26966A1 (es) 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US20040121304A1 (en) 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
WO2006010097A2 (en) 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
AU2005289728B2 (en) 2004-09-22 2011-11-24 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
WO2006111856A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20070167971A1 (en) 2006-01-17 2007-07-19 Raymond Huey Devices and methods for promoting the formation of blood clots in esophageal varices
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
PL1989217T4 (pl) 2006-02-17 2013-02-28 Janssen Pharmaceutica Nv 11-fosforowe pochodne steroidowe użyteczne jako modulatory receptora progesteronu
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
WO2008128783A2 (en) 2007-04-24 2008-10-30 Dsm Ip Assets B.V. Photochemical process for the preparation of a previtamin d
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
JOP20080436B1 (ar) * 2007-10-12 2023-03-28 Novartis Ag تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
EP2249838A4 (en) 2008-02-05 2012-05-02 Harbor Biosciences Inc Pharmaceutical solid state forms
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
EP2412662A4 (en) 2009-03-27 2017-03-29 Komatsu Ltd. Fuel saving control device for working machine and fuel saving control method for working machine
US9074002B2 (en) 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
WO2010141485A1 (en) 2009-06-01 2010-12-09 Samuel Waxman Cancer Research Foundation Compositions and methods to induce differentiation and growth inhibition in breast cancer
EP2454266B1 (en) 2009-07-15 2013-07-10 Cell Therapeutics, Inc. 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
US20110293511A1 (en) 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
US8261855B2 (en) * 2009-11-11 2012-09-11 Flanders Electric, Ltd. Methods and systems for drilling boreholes
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
CN107260746A (zh) * 2010-03-22 2017-10-20 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
CN103442698B (zh) 2010-12-16 2016-10-05 细胞基因公司 难溶性药物的控释口服剂量形式及其用途
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
JP2014510080A (ja) 2011-03-09 2014-04-24 セントローズ, エルエルシー 細胞外標的化薬物複合体
RU2017120977A (ru) 2011-03-11 2018-11-15 Селджин Корпорейшн Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
EP2698634B1 (en) 2011-04-15 2017-11-08 J-Pharma Co., Ltd. Biomarker for breast cancer
MX341147B (es) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Anticuerpos para el tratamiento del cáncer que expresa cldn6.
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
AU2012318618B2 (en) 2011-10-04 2017-01-12 Invivis Pharmaceuticals Inc. Methods and systems for identifying and treating anti-progestin sensitive tumors
WO2013086379A2 (en) 2011-12-08 2013-06-13 Fundacion Sales Methods and compositions for treating antiprogestin-resistant cancers
US20130338016A1 (en) 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
KR20150028232A (ko) 2012-04-27 2015-03-13 리젠츠 오브 더 유니버시티 오브 미네소타 프로게스테론 수용체 서브타입의 유방암 예후, 예측 및 유전자 발현을 토대로 한 항프로게스틴 치료에 대한 반응성 예측 방법
EP2877210A4 (en) 2012-07-24 2016-06-29 Cedars Sinai Medical Center A NEW METHOD FOR DETECTING THE RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
EP2931292B1 (en) 2012-12-13 2018-06-13 Warsaw Orthopedic, Inc. Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
CN113201042A (zh) 2013-03-12 2021-08-03 康泰科思特生物制药公司 奥那司酮多晶型形式和使用方法
US20140363425A1 (en) 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CN103483449A (zh) 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
EP3129786A4 (en) 2014-04-08 2018-03-14 Arno Therapeutics Inc. Systems and methods for identifying progesterone receptor subtypes
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
MX385372B (es) 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
US20170266204A1 (en) 2016-03-21 2017-09-21 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
CN109862907A (zh) 2016-05-02 2019-06-07 泰特拉基因股份有限公司 抗Kv1.3抗体及其生产方法和用途
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3247362A4 (en) 2018-10-10
US20230157960A1 (en) 2023-05-25
RU2017112748A3 (OSRAM) 2019-06-26
JP2017537883A (ja) 2017-12-21
US20160166583A1 (en) 2016-06-16
WO2016081383A1 (en) 2016-05-26
US10786461B2 (en) 2020-09-29
AU2015350241B2 (en) 2021-05-20
MX391191B (es) 2025-03-21
CA2966753A1 (en) 2016-05-26
CN106999501A (zh) 2017-08-01
AU2015350241A1 (en) 2017-05-04
US11672762B2 (en) 2023-06-13
MX2017005163A (es) 2018-01-18
US20210220279A1 (en) 2021-07-22
AU2021218093A1 (en) 2021-09-09
EP3247362A1 (en) 2017-11-29
HK1246653A1 (zh) 2018-09-14
CN106999501B (zh) 2021-08-13
KR20170084086A (ko) 2017-07-19
CN113559075A (zh) 2021-10-29
JP6655075B2 (ja) 2020-02-26

Similar Documents

Publication Publication Date Title
NZ777261A (en) Combination of dextromethorphan and bupropion for treating depression
FI3478286T3 (fi) Menetelmiä munasarjasyövän hoitamiseksi
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
JP2018507243A5 (OSRAM)
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
RU2017134443A (ru) Способ лечения с применением традипитанта
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
PH12018550210A1 (en) Oral dosage form with drug composition, barrier layer and drug layer
WO2014160216A3 (en) Dual targeting anticancer agents
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
JP2016505050A5 (OSRAM)
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
MX2013003523A (es) Composicion farmaceutica de dosis baja.
CR20240015A (es) COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
JP2019535830A5 (OSRAM)
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
JP2016514706A5 (OSRAM)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
RU2016145411A (ru) Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191022